An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lympho...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding CLL/SLL is primarily due to its complex nature and the variability in clinical presentation among patients. Additionally, because CLL/SLL affects a smaller population compared to other cancers, systematic clinical studies have been scarce. This has resulted in a lack of comprehensive data on genetic factors, inheritance patterns, and specific clinical features.
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
There are currently 186 active clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, exploring various treatment options and combinations. Notable FDA-approved therapies include acalabrutinib, alemtuzumab, and venetoclax, among others. Additionally, several orphan drugs are in development, such as Blinatumomab and nemtabrutinib. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=chronic%20lymphocytic%20leukemia%2Fsmall%20lymphocytic%20lymphoma.
Actionable guidance for navigating care for chronic lymphocytic leukemia/small lymphocytic lymphoma
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding CLL/SLL is primarily due to its complex nature and the variability in clinical presentation among patients. Additionally, because CLL/SLL affects a smaller population compared to other cancers, systematic clinical studies have been scarce. This has resulted in a lack of comprehensive data on genetic factors, inheritance patterns, and specific clinical features.
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
There are currently 186 active clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, exploring various treatment options and combinations. Notable FDA-approved therapies include acalabrutinib, alemtuzumab, and venetoclax, among others. Additionally, several orphan drugs are in development, such as Blinatumomab and nemtabrutinib. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=chronic%20lymphocytic%20leukemia%2Fsmall%20lymphocytic%20lymphoma.
Actionable guidance for navigating care for chronic lymphocytic leukemia/small lymphocytic lymphoma
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding CLL/SLL is primarily due to its complex nature and the variability in clinical presentation among patients. Additionally, because CLL/SLL affects a smaller population compared to other cancers, systematic clinical studies have been scarce. This has resulted in a lack of comprehensive data on genetic factors, inheritance patterns, and specific clinical features.
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
There are currently 186 active clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, exploring various treatment options and combinations. Notable FDA-approved therapies include acalabrutinib, alemtuzumab, and venetoclax, among others. Additionally, several orphan drugs are in development, such as Blinatumomab and nemtabrutinib. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=chronic%20lymphocytic%20leukemia%2Fsmall%20lymphocytic%20lymphoma.
Actionable guidance for navigating care for chronic lymphocytic leukemia/small lymphocytic lymphoma
To navigate your care for CLL/SLL, consider consulting with a hematologist who specializes in lymphoproliferative disorders. They can provide tailored treatment options and monitor your condition closely. Additionally, look for clinical trials that may offer access to new therapies; you can find these on ClinicalTrials.gov. For support resources, the National Organization for Rare Disorders (NORD) at rarediseases.org may have relevant information, even if specific patient organizations are not identified for CLL/SLL. Engaging with a genetic counselor could also be beneficial, especially if you have concerns about familial risk.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.